Skip to main content

Community Series in the Role of Multi-omics Variants in Tumor Immunity and Immunotherapy: Volume II

91kviews
ORIGINAL RESEARCH
7 February 2023
Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets
Rui Ferreira Marques, 10 more and Rui Manuel Reis

6,792 views

28 citations

ORIGINAL RESEARCH
29 August 2023
Pan-cancer analysis of kinesin family members with potential implications in prognosis and immunological role in human cancer
Ming Zhong, 12 more and Zhihua Zheng

5,170 views

17 citations

ORIGINAL RESEARCH
9 February 2023
Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma
Feng Li, 8 more and Yousheng Mao

4,656 views

11 citations

IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures
ORIGINAL RESEARCH
2 July 2021
IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures
Dongqiang Zeng, 13 more and Wangjun Liao
Recent advances in next-generation sequencing (NGS) technologies have triggered the rapid accumulation of publicly available multi-omics datasets. The application of integrated omics to explore robust signatures for clinical translation is increasingly emphasized, and this is attributed to the clinical success of immune checkpoint blockades in diverse malignancies. However, effective tools for comprehensively interpreting multi-omics data are still warranted to provide increased granularity into the intrinsic mechanism of oncogenesis and immunotherapeutic sensitivity. Therefore, we developed a computational tool for effective Immuno-Oncology Biological Research (IOBR), providing a comprehensive investigation of the estimation of reported or user-built signatures, TME deconvolution, and signature construction based on multi-omics data. Notably, IOBR offers batch analyses of these signatures and their correlations with clinical phenotypes, long non-coding RNA (lncRNA) profiling, genomic characteristics, and signatures generated from single-cell RNA sequencing (scRNA-seq) data in different cancer settings. Additionally, IOBR integrates multiple existing microenvironmental deconvolution methodologies and signature construction tools for convenient comparison and selection. Collectively, IOBR is a user-friendly tool for leveraging multi-omics data to facilitate immuno-oncology exploration and to unveil tumor-immune interactions, and accelerating precision immunotherapy.

28,730 views

1,281 citations

METHODS
13 April 2021
NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy
Jiaqi Xia, 6 more and Yu Zhou

10,830 views

76 citations